Tag
A comprehensive review of the ACHIEVE-4 trial confirms orforglipron’s cardiovascular safety non-inferior to insulin glargine in type 2 diabetes patients at elevated cardiovascular risk, highlighting its oral administration and safety
This phase 3 trial evaluates the 52-week safety of oral orforglipron in Japanese adults with type 2 diabetes, showing an acceptable safety profile when used alongside diet, exercise, and oral antihyperglycemic drugs.
The ACHIEVE-3 phase 3 trial demonstrates that orforglipron, a novel non-peptide oral GLP-1 receptor agonist, provides superior glycemic control compared to oral semaglutide in adults with type 2 diabetes, despite a higher frequency of gastr
In ATTAIN‑2, oral orforglipron produced dose‑dependent, statistically superior weight loss and improved HbA1c versus placebo over 72 weeks in adults with overweight/obesity and type 2 diabetes, with an adverse‑event profile dominated by gas
Orforglipron, a novel oral GLP-1 receptor agonist, demonstrated significant and sustained weight reduction in obese adults without diabetes in a 72-week phase 3 trial, with a tolerable safety profile consistent with existing GLP-1 therapies
Orforglipron demonstrates significant glycemic control and weight reduction benefits in early type 2 diabetes and obesity, with favorable safety and oral administration convenience.
Eli Lilly’s oral GLP-1 drug orforglipron marks a milestone in obesity treatment, yet competition from novel oral therapies by Novo Nordisk, Viking Therapeutics, Roche, Terns Pharmaceuticals, and Rhythm Pharmaceuticals is intensifying,
